Abstract
What is the mechanism behind acute bilineage leukemia (ie, 2 separate populations of myeloid and lymphoid blasts)? Why does the risk for therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) last only 10 years, while the risk for therapy-related solid tumors can be lifelong
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
